This paper provides a comprehensive overview of lung cancer, a malignant tumor characterized by uncontrolled cell growth in lung tissues. It examines the primary types of lung cancer, including small-cell and non-small-cell carcinomas, and details the respiratory, systemic, and paraneoplastic symptoms that indicate disease presence. The paper discusses diagnostic procedures such as chest radiography, CT imaging, and biopsy techniques, then outlines treatment modalities including chemotherapy, radiation therapy, surgery, and emerging targeted therapies that inhibit epigenetic mechanisms. The role of palliative care in supporting patients throughout treatment is also addressed.
Lung cancer, popularly known as pulmonary carcinoma or lung carcinoma, is defined as a malignant tumor in the lungs featuring uncontrolled cell growth in lung tissues. If left untreated, the growth spreads beyond the lungs through the metastasis process into adjacent tissues and other body parts. Most cancers originating in the lungs are classified as primary lung cancers, which are carcinomas derived from the epithelial cells. The major types of lung cancer include small-cell lung carcinoma and non-small-cell lung carcinoma (Leary, 2012). Common symptoms of lung cancer include coughing (sometimes with blood), shortness of breath, chest pains, and weight loss.
Lung cancer presents through multiple symptom categories that reflect different disease mechanisms. Respiratory indicators include coughing up blood, persistent rough coughing, and shortness of breath or wheezing. These direct airway symptoms often prompt initial medical evaluation. Systemic symptoms—those affecting the body as a whole—include fever, weight loss, fatigue, and clubbing (enlargement) of the fingernails (Argiris, 2012).
A third symptom category results from the cancer mass pressing against adjacent structures. These include bone pain, chest pain, difficulty swallowing, and superior vena cava obstruction, which occurs when the tumor compresses the large vein returning blood to the heart. As cancer increases along the airways, it obstructs airflow and causes breathing difficulties. This obstruction leads to accumulation of secretions behind the blockage and predisposes patients to secondary pneumonia.
Beyond symptoms directly caused by the tumor's physical presence, paraneoplastic phenomena—systemic effects not directly related to local cancer presence—may draw attention to the disease. Lung cancer can trigger Lambert-Eaton myasthenic syndrome, in which autoantibodies weaken muscle function. Other paraneoplastic effects include hypercalcemia (abnormally elevated blood calcium) or inappropriate antidiuretic hormone syndrome, which causes abnormal concentration and dilution of blood and urine (Leary, 2012).
Cancer develops through epigenetic changes and genetic DNA damage that influence normal cell functions such as cell proliferation, DNA repair, and apoptosis (programmed cell death). As damage accumulates, the risk of cancer development increases significantly.
When patients report symptoms suggesting lung cancer, diagnosis typically begins with a chest radiograph, which can reveal obvious masses and widening of the mediastinum (the central compartment of the thorax) that suggests spread of lymph nodes. Other radiographic findings include atelectasis (collapse of lung tissue), pleural effusion (fluid around the lungs), or consolidation (pneumonia-like appearance) (Timmermann, 2013). CT imaging is one of the most typical and informative approaches, providing detailed information regarding disease type and extent.
To obtain definitive diagnosis, CT-guided biopsy or bronchoscopy is used to sample the tumor's histopathology. Lung cancers are classified based on their histological types—the microscopic appearance and size of malignant cells viewed by a pathologist. This classification is critical because it determines management strategy and predicts disease outcomes. Lung carcinomas fall into two distinguished classes for therapeutic purposes: small-cell lung carcinoma and non-small-cell lung carcinoma (Argiris, 2012).
Lung cancer treatment is tailored based on the specific cell type, the extent of disease spread, and the patient's performance status. The common treatments in healthcare include chemotherapy, radiation therapy, surgery, and palliative care (Timmermann, 2013). Targeted lung cancer therapy continues to grow in relevance for advanced lung cancer management.
Radiotherapy is often given alongside chemotherapy when curative intent is pursued and the patient is ineligible for surgery (Leary, 2012). High-intensity radiotherapy is referred to as radical radiotherapy. Refinement of technique continues through approaches such as hypofractionated-accelerated radiotherapy, in which high radiotherapy doses are delivered within shorter time periods (Timmermann, 2013).
Beyond conventional approaches, various drugs targeting epigenetic mechanisms are under review and development. Development of histone deacetylase inhibitors has led to clinical use of valproic acid, vorinostat, panobinostat, and other agents. DNA methyltransferase inhibitors across various development stages include azacytidine, hydralazine, and decitabine (Argiris, 2012). These targeted therapies represent an evolution toward more precise, mechanism-based cancer treatment.
"Supportive care role in comprehensive cancer management"
Always verify citation format against your institution’s current style guide requirements.